> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ionis Lowers TRYNGOLZA Outlook To About $50 Million — But Keeps Companywide Revenue Forecast
- URL: https://www.bullished.co/ionis-lowers-tryngolza-outlook-to-about-50-million-but-keeps-companywide-revenue-forecast-b372de22/
- Published: 2026-11-09T12:06:21.000Z
- Updated: 2026-11-09T12:06:21.000Z
- Description: DAWNZERA sales and research partnerships lift third-quarter revenue while Ionis spends more on launching its own medicines.
- Author: Matteo Parrino
- Tags: Earnings, IONS, Industry: Healthcare

[Ionis Pharmaceuticals](https://www.bullished.co/tag/ions/), which develops RNA-targeted medicines for serious diseases, cut its 2026 TRYNGOLZA sales outlook Monday to [approximately $50 million](https://www.sec.gov/Archives/edgar/data/0000874015/000114036126042598/ef20085128%5F8k.htm?ref=bullished.co), from $100-110 million, according to the earnings release accompanying its SEC filing. Adoption of the treatment for severely elevated triglycerides has been slower than management anticipated, but Ionis kept its companywide revenue forecast at $875-900 million.

## DAWNZERA Carries Commercial Growth

TRYNGOLZA brought in $9 million during the third quarter, compared with $32 million in the same quarter of 2025\. DAWNZERA moved in the opposite direction: its [sales reached $37 million](https://www.sec.gov/Archives/edgar/data/0000874015/000114036126042598/ef20085128%5Fex99-1.htm?ref=bullished.co), against $1 million a year earlier, and Ionis retained its $110-120 million full-year forecast for that medicine.

The treatments serve different patients. TRYNGOLZA is approved alongside diet to lower triglycerides and the risk of acute pancreatitis in adults with severely elevated triglycerides. DAWNZERA prevents hereditary angioedema attacks in patients aged 12 and older.

Ionis sells both medicines itself in the U.S., part of a business that combines independent drug launches with partner-led sales and royalties. Its newly launched Alexander disease treatment, ZANVASTRO, added $2 million in quarterly sales, with the first patients receiving commercial supplies.

Commercial revenue totaled $136 million, up 18% from a year earlier, primarily because of DAWNZERA. SPINRAZA contributed $69 million in royalties, compared with $56 million, while WAINUA royalties fell to $7 million from $13 million.

## Partnership Payments Lift The Quarter

Total third-quarter revenue reached $243 million, compared with $157 million a year earlier. Research and development partnerships contributed $107 million, against $41 million, as programs advanced and triggered payments.

The longer-period comparison needs a different lens. Revenue for the first nine months was $757 million, versus $740 million in 2025, when Ionis received a [$280 million upfront](https://www.sec.gov/Archives/edgar/data/0000874015/000114036126042598/ef20085128%5Fex99-1.htm?ref=bullished.co) licensing payment from Ono Pharmaceutical for sapablursen in the second quarter. Excluding that one-time payment, Ionis reported nine-month revenue growth of 64%.

Spending also rose as Ionis invested in commercializing TRYNGOLZA, DAWNZERA and ZANVASTRO. Third-quarter operating expenses were $373 million, compared with $317 million; the operating loss nevertheless narrowed to $130 million from $160 million. Excluding non-cash stock-based pay, the quarterly operating loss was $87 million, versus $129 million.

## Cash Forecast Holds Through Launch Spending

Ionis kept its full-year adjusted operating-loss forecast at $425-475 million, excluding stock-based compensation, and still expects more than $1.6 billion in cash, cash equivalents and short-term investments at year-end.

That cash balance stood at $1.9 billion at the end of the third quarter, down from $2.7 billion at year-end 2025\. Ionis attributed the decline primarily to repaying convertible debt and funding operations.

Elizabeth L. Hougen, Ionis' chief financial officer, said the company remains committed to “achieving our goal of sustained positive cash flow and long-term value creation.” Her statement also maintained management's expectation that TRYNGOLZA could eventually generate multi-billion-dollar peak sales, despite the reduced near-term outlook.

Ionis expects a European approval decision in the fourth quarter of 2026 for TRYNGOLZA's use in adults with severely elevated triglycerides, following a positive opinion from the Committee for Medicinal Products for Human Use.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — IONIS PHARMACEUTICALS INC (IONS)](https://www.sec.gov/Archives/edgar/data/0000874015/000114036126042598/ef20085128%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ef20085128\_ex99-1.htm — IONIS PHARMACEUTICALS INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000874015/000114036126042598/ef20085128%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR

### More on Ionis Pharmaceuticals

- [Roche's Sefaxersen Cuts Protein Loss 43.1% In Late-Stage Kidney Trial Of Ionis-Discovered Drug](https://www.bullished.co/roches-sefaxersen-cuts-protein-loss-43-1-in-late-stage-kidney-trial-of-ionis-discovered-0b4dc20e/)
- [FDA Approves Hibsago, GSK's Hepatitis B Drug From Ionis, With 10-12% Royalties And A Boxed Warning](https://www.bullished.co/fda-approves-hibsago-gsks-hepatitis-b-drug-from-ionis-with-10-12-royalties-and-a-boxed-5562e0e0/)

[All Ionis Pharmaceuticals (IONS) coverage →](https://www.bullished.co/tag/ions/)